Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7457.074 | 0.0343 | -0.7406 | 1.6514 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7457.074 | 0.0057 | -0.9124 | 1.6514 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7457.074 | 0.0057 | -0.9124 | 1.6514 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7457.074 | 0.0099 | -0.8779 | 1.6514 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7457.074 | 0.0099 | -0.8779 | 1.6514 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 7457.074 | 0.0105 | -0.8730 | 1.6514 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 7457.074 | 0.0105 | -0.8730 | 1.6514 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14735.203 | 0.9470 | 0.9476 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14735.203 | 0.9470 | 0.9476 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14735.203 | 0.7540 | 0.7426 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14735.203 | 0.7540 | 0.7426 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14735.203 | 0.6639 | 0.6377 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14735.203 | 0.6639 | 0.6377 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14735.203 | 0.1396 | -0.2346 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14735.203 | 0.1396 | -0.2346 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14735.203 | 0.0155 | -0.7383 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14735.203 | 0.0155 | -0.7383 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14735.203 | 0.0067 | -0.8260 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14735.203 | 0.0067 | -0.8260 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14735.203 | 0.0053 | -0.8445 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14735.203 | 0.0053 | -0.8445 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14735.203 | 0.0114 | -0.7742 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14735.203 | 0.0114 | -0.7742 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14735.203 | 0.0080 | -0.8105 | 2.0496 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14735.203 | 0.0080 | -0.8105 | 2.0496 |